For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.
Survivors of childhood low-grade gliomas treated with radiotherapy have poorer neuropsychological and socioeconomic-status (SES) outcomes.
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
Computer-assisted diagnosis (CAD) can help physicians detect growth of low-grade gliomas.
Entrectinib showed activity and appeared to be safe in pediatric patients with recurrent or refractory solid tumors harboring NTRK1/2/3, ROS1, or ALK aberrations.
AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.
This study involved the engineering of CAR-T cells specific for the EGFRvIII antigen to also secrete bispecific T cell engagers (BiTEs) against wild-type EGFR.
The researchers speculated that the delivery of alternating electric fields to GBM cells may facilitate the delivery of chemotherapy.
The neuronal loss and neurological dysfunction caused by solid stress from brain tumors was reversed by lithium in mice models.
Clinical application of cerebrospinal fluid ctDNA analysis remains unclear.
New research proposes a novel mechanism for how tumors sidestep the immune system in patients with intracranial tumors.
The FDA based its approval on findings from a single-arm phase 2 study, in which researchers treated 68 patients with iobenguane I 131 intravenous injection.
In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.
EGFR-amplified tumors had a high rate of response.
Researchers enrolled 66 patients with glioblastoma to evaluate the safety and efficacy of upfront temozolomide with bevacizumab.
A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.
Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.
Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.
Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.